Related Experiment Video
Updated: Mar 2, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
CIB1 is a regulator of pathological cardiac hypertrophy
Joerg Heineke1, Mannix Auger-Messier, Robert N Correll
1Howard Hughes Medical Institute, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA. Heineke.Joerg@mh-hannover.de
Insights
Calcium and Integrin Binding Protein-1 (CIB1) regulates cardiomyocyte hypertrophy by anchoring calcineurin to the sarcolemma. CIB1 is crucial for pathological cardiac hypertrophy but not physiological responses.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Cell Signaling
Background:
- Hypertrophic heart disease is a significant health concern in Western nations.
- Identifying novel regulators of cardiomyocyte hypertrophy is critical for therapeutic development.
Purpose of the Study:
- To identify novel regulators of cardiomyocyte hypertrophy.
- To elucidate the role of Calcium and Integrin Binding Protein-1 (CIB1) in cardiac hypertrophy.
Main Methods:
- Yeast two-hybrid screening to identify CIB1-interacting partners.
- Localization studies in mouse and human myocardium.
- Analysis of CIB1 expression and membrane association in physiological and pathological hypertrophy.
- Phenotypic analysis of CIB1-deleted and CIB1-overexpressing mice under pressure overload and exercise stimuli.
Main Results:
- CIB1 interacts with calcineurin B, a subunit of calcineurin.
- CIB1 anchors calcineurin to the sarcolemma, regulating its activation.
- CIB1 levels and membrane association increase in pathological hypertrophy.
- Cib1 deletion attenuates pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction.
- CIB1 deletion does not affect exercise-induced physiological hypertrophy.
- CIB1 overexpression exacerbates cardiac hypertrophy.
Conclusions:
- CIB1 is a novel regulator of cardiac hypertrophy.
- CIB1 mediates pathological cardiac hypertrophy by controlling calcineurin localization and activation at the sarcolemma.
- CIB1 represents a potential therapeutic target for hypertrophic heart disease.
Abstract:
Hypertrophic heart disease is a leading health problem in Western countries. Here we identified the small EF hand domain-containing protein Ca(2+) and integrin-binding protein-1 (CIB1) in a screen for previously unknown regulators of cardiomyocyte hypertrophy. Yeast two-hybrid screening for CIB1-interacting partners identified a related EF hand domain-containing protein, calcineurin B, the regulatory subunit of the prohypertrophic protein phosphatase calcineurin. CIB1 localizes primarily to the sarcolemma in mouse and human myocardium, where it anchors calcineurin to control its activation in coordination with the L-type Ca(2+) channel. CIB1 protein amounts and membrane association were enhanced in cardiac pathological hypertrophy, but not in physiological hypertrophy. Consistent with these observations, Cib1-deleted mice showed a marked reduction in myocardial hypertrophy, fibrosis, cardiac dysfunction and calcineurin-nuclear factor of activated T cells (NFAT) activity after pressure overload, whereas the degree of physiologic hypertrophy after swimming exercise was not altered. Transgenic mice with inducible and cardiac-specific overexpression of CIB1 showed enhanced cardiac hypertrophy in response to pressure overload or calcineurin signaling. Moreover, mice lacking Ppp3cb (encoding calcineurin A, beta isozyme) showed no enhancement in cardiac hypertrophy associated with CIB1 overexpression. Thus, CIB1 functions as a previously undescribed regulator of cardiac hypertrophy through its ability to regulate the association of calcineurin with the sarcolemma and its activation.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure II: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pathophysiology of Heart Failure
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

